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Abstract: Visceral leishmaniasis (VL) is a life-threatening disease. Traditional treatment with 
pentavalent antimony injections has become ineffective in the area with the world’s highest 
prevalence of disease (North Bihar, India) and is becoming less effective elsewhere as well. 
A replacement is needed, best if it can be given to more patients outside the hospital. Miltefosine 
is the ﬁ  rst oral drug registered for VL. Given daily under medical supervision for 4 weeks, it 
cures 94% of patients (both children and adults) and is reasonably safe. Miltefosine has great 
potential for improving access to treatment and overall control of VL and will be critical in the 
VL elimination campaign in the Indian subcontinent, but must be safeguarded or will be lost if 
misused. Its main limitations are adherence (and hence potential for selection of drug resistant 
parasites) and teratogenicity (pregnancy must be avoided during treatment and the following two 
months). This calls for responsible deployment, setting in place mechanisms to protect female 
patients in child-bearing age, monitoring effects and optimizing adherence in real-life condi-
tions through directly observed therapy. One option to protect the useful life-span of miltefosine 
consists in shortening treatment duration by combining it with another drug.
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Introduction
Of all forms of leishmaniasis, visceral leishmaniasis (VL, kala-azar) is the most severe, 
and can be fatal without treatment. VL occurs worldwide, but 90% of the cases are in 
ﬁ  ve countries: north-eastern India, Bangladesh, and Nepal in the Indian subcontinent, 
Sudan in Africa and north-eastern Brazil in South America (WHO 2000). India alone 
shares almost 50% of the world’s burden of disease. Here, pentavalent antimony has 
become ineffective in the 1990’s in most of the high-burden areas of North Bihar except 
few eastern districts, and must be replaced. However, none of the traditional alterna-
tives was satisfactory: pentamidine is no longer used; amphotericin B deoxycholate 
is impractical (hospitalization and several infusions required, risk of immediate and 
delayed toxicity) and severely dependent upon the availability of hospital beds; and 
liposomal amphotericin B is unaffordable. A replacement was needed urgently.
Oral drugs are very convenient as the need for hospitalization and related costs are 
eliminated, home treatment is possible, coverage and access is better. Past attempts 
to develop oral drugs have failed with allopurinol, ketoconazole, ﬂ  uconazole, and 
atovaquone.
Miltefosine (hexadecylphosphocholine, HePC), an alkyl phospholipids compound, 
was originally intended for breast cancer and other solid tumors. However, it could 
not be developed as an oral agent because of dose-limiting gastro-intestinal toxicity, 
and only a topical formulation is approved for skin metastases (Verweij et al 1992; 
Dummer et al 1993). Then came the evidence of excellent antileishmanial activity Therapeutics and Clinical Risk Management 2007:3(5) 734
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both in vitro and in experimental animals (Croft et al 1987, 
1996; Kuhlencord et al 1992). This, and the fact that the drug 
was already approved for human trials, prompted the clinical 
assessment of oral miltefosine in human visceral leishmani-
asis in1996. Clinical trials were aimed ﬁ  rst at ﬁ  nding an 
effective and safe treatment schedule (phase I/II) and then 
conﬁ  rming its properties in comparative Phase III studies. 
The initial evidence of clinical efﬁ  cacy came from the collab-
orative efforts of Banaras Hindu University, Varanasi India, 
Cornell University, New York and Asta Medica, Frankfurt 
(the manufacturer of the drug). The results of these studies 
resulted in the involvement of WHO/TDR, Geneva and the 
Indian Council of Medical Research (ICMR), New Delhi 
along with Asta Medica, which by then had become Zentaris. 
The results of these clinical studies, along with chemistry, 
manufacturing and non-clinical data, were compiled in a 
dossier submitted by the manufacturer for licensure (Berman 
2005; Sindermann and Engel 2006).
Mechanism of action
Miltefosine is effective in vitro against both promastigotes 
and amastigotes of various species of Leishmania (Croft et al 
1987, 1996; Escobar et al 2002), and also other kinetoplas-
tidae (Trypanosoma cruzi,T. brucei) and other protozoan 
parasites (Entamoeba histolytica, Acanthamoeba)
Like other alkyl-lysophospholipids the mechanism of 
action of miltefosine is only partly known; most data are 
in tumor cell lines as an anti-cancer agent where these 
compounds can trigger programmed cell death (apoptosis) 
(Wieder et al 1999; Rybczynska et al 2001; Wright et al 
2004). Extension to Leishmania has come from similarities 
between metazoan and protozoan apoptosis, and work on 
drug-resistant parasites.
Evidence of apoptosis-like death has been shown in 
L. donovani promastigotes treated with miltefosine (Paris 
et al 2004; Verma and Dey 2004). However, how this family 
of compounds induces apoptosis in either mammalian cells 
or parasites is not entirely clear. A prevalent though not yet 
fully established hypothesis is inhibition of the synthesis 
of phosphatidyl choline (PC), an essential element in the 
synthesis and integrity of cellular membranes and a source 
of signaling molecules (Arthur and Bittman 1998; Cui and 
Houweling 2002; Wright et al 2004).
In order for these effects to manifest with lysophosphati-
dylcholine analogues, intracellular accumulation is required 
(Gajate and Mollinedo 2002); resistant cell lines prove to 
accumulate less drug (Perez-Victoria, Castanys et al 2003). 
Drug accumulation is a three-step process which appears 
to be common to eukaryotic cells, whereby the drug binds 
to the cell plasma membrane, enters the cell and reaches its 
target.
A current hypothesis is that phospholipids and phos-
phocholine derivatives such as edelfosine and presumably 
miltefosine move across membranes (from the outer to the 
inner layer) via inward translocation (also termed inward 
transbilayer movement, or flip), an energy-dependent, 
protein-mediated process.
For drug binding, the phospholipid composition of cell 
membranes seems critical: miltefosine resistant L. donovani 
have altered fatty acid elongation and unsaturation, and 
the C-24-alkylation of sterols (Rakotomanga et al 2005). 
For transport across the membrane, a putative transporter 
was recently identiﬁ  ed; a Leishmania P-type ATPase gene, 
belonging to the aminophospholipid translocase (APT) sub-
family termed LdMT (L. donovani Miltefosine Transporter) 
has been cloned. LdMT is expressed in the plasma membrane 
where it mediates the translocation of phospholipids across the 
plasma membrane in Leishmania parasites (Perez-Victoria, 
Gamarro et al 2003).
As Leishmania amastigotes reside inside macrophages, 
membrane binding and ﬂ  ip-ﬂ  opping will have to occur mul-
tiple times across the various membranes until equilibrium is 
reached. Leishmania parasites do not seem to have the ability 
to metabolize miltefosine, but can extrude via either exocy-
tosis or protein-dependent ﬂ  op across the plasma membrane 
(possibly by proteins of the ABC transporters family, such as 
P-glycoprotein (mdr1) (Perez-Victoria et al 2001).
Clinical studies
Clinical studies for VL in adults
Phase I/II
The ﬁ  rst clinical study was a phase I/II dose escalation trial 
in which miltefosine was used in a daily dose ranging from 
50 mg on alternate days to 250 mg daily for 28 days. In this 
study only adult males (aged 14–65 years) were enrolled in 
six cohorts of ﬁ  ve patients each. Those with hepatic, cardiac 
or retinal diseases or other serious concurrent disorders were 
excluded. Patients could be enrolled in the next dose level 
only after three patients in the previous group had completed 
28 days of therapy without developing serious side effects. 
The maximum tolerated dose level was deﬁ  ned as one dose 
level below the dose not tolerated by at least three of the 
ﬁ  ve patients. Initial cure was deﬁ  ned as absence of fever, 
reduction in spleen size and absence of parasites in splenic 
aspirate. For deﬁ  nite cure patients had to be asymptomatic 
with parasite free splenic/bone-marrow aspirate smear at Therapeutics and Clinical Risk Management 2007:3(5) 735
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six month follow-up and absence of signs and symptoms 
of relapse two months later (eight months after treatment). 
In the later trials of miltefosine, ﬁ  nal cure was deﬁ  ned as 
initial cure followed by absence of signs and symptoms of 
relapse at six month follow up.
Fourteen (47%) patients had received previous antileish-
manial treatment, and either failed to respond or relapsed after 
treatment with antimonials (20 mg/kg/day for 28 days). 
Overall clinical and parasitological responses to miltefosine 
were rapid in all groups. On day 14, 28 of the 30 patients had 
parasite-free splenic aspirate, and the majority of patients had 
become afebrile by day 7.
Tolerability. As expected, gastrointestinal (GI) symptoms 
were the principal toxic effects: 26 (87%) patients had one or 
more episodes of both vomiting and diarrhea (n = 15; 50%), 
nausea and vomiting alone (n = 9; 30%) or diarrhea alone (n 
= 2; 7%). 72% episodes of vomiting lasted 1 day or less, and 
53% involved a single episode during the entire treatment 
period; similarly 65% of the episodes of diarrhea lasted 1 day 
or less, and 33% involved a single episode. Severe vomiting 
or diarrhea (grade III) occurred in ﬁ  ve patients (one on 200 
mg and four on 250 mg miltefosine daily). In groups 1–4 
(50 mg e.o.d, 100 mg e.o.d., 100 mg q.d., 150 mg q.d.) the 
GI side-effects were grade I and II (mild or moderate) only, 
and did not require treatment withdrawal. The maximum 
tolerated dose in this study was 200 mg q.d. One patient 
in group 6 (250 mg q.d.), aged 35 year, died on day 21. He 
was responding to miltefosine with decrease in fever, spleen 
size and splenic aspirate score and weight gain, however, his 
serum creatinine rose from 88.4 µmol/L to 274.04 µmol/L on 
day 14, and was removed from the study on day 19 because 
of profuse diarrhea. He died unexpectedly 2 days later despite 
supportive care (Sundar et al 1998).
Efﬁ  cacy. Eight patients, who had completed 28 days of 
therapy, relapsed; seven were from lower dose alternate day 
regimen (3 and 4 from group 1 and 2 who received 50 and 
100 mg of the drug on alternate days, respectively), and one 
from group 4. These were retreated successfully with ampho-
tericin B (1 mg/kg × 15 infusions e.o.d.). The remaining 21 
were healthy without any sign or symptoms of the disease, 
and each had a parasite free smear bone marrow aspirate 
smear at 6 month follow-up. Two months later, all 21 patients 
were well, including 12 who had failed on a previous course 
with sodium stibogluconate (Sundar et al 1998).
This study though in a small number of patients clearly 
indicated that: (i) oral miltefosine was clearly and rapidly 
active against Indian VL; (ii) a daily dose up to 150 mg was 
well tolerated; (iii) 90% (9/10) on 100–150 mg/day group had 
long term cures; (iv) as expected the main toxic effects were 
GI; no retinal toxicity was seen; however, (v) nephrotoxicity 
occurred in one patient on the high dose (250 mg/day).
This preliminary study allowed selecting a dose of 
100–150 mg per day as reasonably effective and safe.
Phase II studies
Three phase two studies were done.
Phase II dose-ﬁ  nding study
First was a three arm comparative trial including both sexes; 
patients were randomized to receive 28 days of oral milt-
efosine treatment at 100, 150 or 200 mg per day. Women of 
childbearing age were required to use adequate contraception 
during and for two months after the treatment. While a sample 
size of 18 patients was estimated for each of the three treat-
ment arms, the eighth, ninth and tenth subjects in the 200 mg 
per day group developed serious adverse reactions, and after 
an interim review, this arm was closed. All subsequently 
enrolled patients were randomized to receive 100 or 150 mg 
per day until the target number was reached in these dose 
groups. Seventeen (38%) of 45 enrolled patients had failed 
to respond to previous antileishmanial treatment.
Tolerability. Treatment was discontinued in ﬁ  ve patients 
before day 14. One patient receiving 100 mg/day withdrew 
on day 5 and was lost to follow-up; four others (one receiving 
150 mg/day and three on 200 mg/day) were removed from 
the study on days 7–11 because of grade III toxicity, one each 
because of vomiting (150 mg/day), diarrhea, hepatotoxicity 
and diarrhea, and nephrotoxicity; two additional patients 
(one each on 100 and 150 mg/day) were removed on day 15 
and 17 because of grade III vomiting or diarrhea. However, 
these six continued to improve clinically and did not require 
rescue treatment.
As anticipated, the primary adverse reactions to miltefo-
sine were gastrointestinal: vomiting alone (n = 13), diarrhea 
alone (n = 5) or both reactions (n = 18). Vomiting was mild in 
most subjects and there were only 1–2 episodes of vomiting 
during the entire duration of treatment for most subjects 
except two in whom it was severe. A similar pattern was 
observed with diarrhea with all but three patients having 
mild episodes.
Thirteen (29%) patients developed reversible nephrotox-
icity, mild (grade I) in 11 and moderate (grade II) in one, 
returning to baseline values while treatment was continued. 
In one patient on 200 mg/day, creatinine and BUN con-
centration rose from 1.0 and 13 mg/dl to 8.0 and 62 mg/dl, 
respectively, on day 7 (grade III toxicity), and treatment was Therapeutics and Clinical Risk Management 2007:3(5) 736
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stopped; 1 week later the levels returned to 1.2 and 17 mg/dl 
respectively. In 12 (27%) patients elevation of hepatic trans-
aminases was seen, and in 11 it promptly returning back to 
normal. In one patient (on 200 mg/day miltefosine) severe 
rise in enzymes necessitated stoppage of treatment (Sundar 
et al 1999).
Efﬁ  cacy. Overall clinical and parasitologic responses to 
miltefosine were rapid. At six months, 44 patients (98%, CI 
88%–100%) were complete responders (deﬁ  nitive cures) 
including the six treated for 7–17 days. The only subject 
considered as treatment failure was the one on 100 mg milt-
efosine/day who was lost to follow-up. These results recon-
ﬁ  rmed that 100–150 mg/day of miltefosine for 28 days was 
likely to be an effective therapeutic option for VL, including 
antimony-unresponsive infections (Kumar et al 1999).
Phase II multicentre dose and schedule ﬁ  nding study
This trial was done in three centers testing four regimens, of 
which two with a lower dose during ﬁ  rst week, followed by 
full doses in the next three weeks.
Tolerability. GI side effects were frequent (62% of patients) 
but mild to moderate in severity (grade I or II) and no patient 
had to discontinue therapy. There was a mean weight gain 
of 2.0 kg during therapy. Liver and kidney function tests 
were occasionally and rarely abnormal, respectively. In 
the two cases of premature termination of therapy due to 
elevated levels of SGOT and creatinine, respectively, values 
rapidly normalized after therapy had been stopped (Jha et al 
1999).
Efﬁ  cacy. All the 120 total patients enrolled were initially 
cured when tested 2 weeks after the end of therapy. The ﬁ  nal 
cure rate was 93% (95% CI 78–99) in patients either receiving 
50 mg/day for six weeks or 50 mg/day for the ﬁ  rst week fol-
lowed by 100 mg/day for the next three weeks, and was 97% 
(95% CI 83–100) in patients on 100 mg/day or 100 mg/day 
for the ﬁ  rst week followed by 150 mg (Jha et al 1999).
Phase II duration ranging trial
In view of the kinetics of the response to miltefosine, which 
included parasitological cure being observed in most of the 
patients at day 14, and the experience in the 10 subjects 
cured after abbreviated therapy, courses of treatment shorter 
than 28 days were also considered. To test this hypothesis, 
we selected the best tolerated daily regimen (100 mg) and 
administered it for 2, 3 or 4 weeks to 18 patients each.
Except for one subject on the 2 week regimen, all 53 
others improved and parasite were undetectable in splenic 
smears, and thus were labeled as apparent cure. During the 
six months of follow up, one patient treated for two weeks 
relapsed, while the remaining 52 patients remained negative. 
The ﬁ  nal cure rates were 16/18 (89%, CI 65%–99%) on the 
2-week regimen, and 18/18 (100%, CI 85%–100%) in those 
treated for either 3 or 4 weeks. Although the sample size was 
small, this study indicated that miltefosine for 2 or 3 weeks 
would be able to cure 90% patients (Sundar et al 2000).
Phase III pivotal study
The above mentioned studies allowed to select the optimal 
dose, which was compared, in a pivotal phase III study 
with the aim to obtaining regulatory approval for the indi-
cation, to the most effective standard treatment of VL ie, 
amphotericin B. This was a multicentric, randomized, open 
label study enrolling 299 VL patients (12 years and above) 
on miltefosine at the dose of 50 mg (if weighing  25 kg) 
or 100 mg (25 kg) daily for 28 days, and 99 patients on 
amphotericin B at the dose of 1 mg/kg every other day for 
a total of 15 infusions.
Tolerability. Vomiting and diarrhea were the commonest 
adverse effect with Miltefosine (occurring in 38% and 20% 
patients respectively.) In most cases, the event was self limit-
ing, lasting for 1–2 days and did not require withdrawal of 
treatment. Transient rise in transaminases occurred in 15% 
of the patients in the ﬁ  rst two weeks of treatment, and then 
the levels started normalizing by the end of the 2nd week. 
Renal dysfunction with mild rise in blood urea and serum 
creatinine was observed in 10% of the patients but it did not 
lead to withdrawal of drug and normalized gradually during 
the course of treatment.
Overall, nine patients in Miltefosine group did not 
complete treatment: one patient withdrew from the study, 
while in the remaining eight treatments was discontinued pre-
maturely due to lack of tolerance or intercurrent illness. Four 
out of these eight patients did not turn up for 6-month follow 
up visit while of the remaining four who were available, 
three achieved ﬁ  nal cure while one relapsed. Three of these 
patients, who ultimately went on to achieve ﬁ  nal cure despite 
not completing treatment, withdrew on the 6th day (Stevens 
Johnson syndrome), 14th day (elevated bilirubin) and 21st 
day (bleeding hemorrhoids ), while the one who relapsed at 
6 months discontinued the treatment on the 11th day because 
of arthritis and rashes (Sundar et al 2002).
Efﬁ  cacy.  At the end of treatment both groups achieved 100% 
parasitological cure in the patients available for evaluation 
(Miltefosine n = 293; amphotericin B n = 96). At 6 month fol-
low up, 9 (3%) relapsed in the Miltefosine group while none 
relapsed in the amphotericin B group. In the former group, Therapeutics and Clinical Risk Management 2007:3(5) 737
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at the end of the treatment parasitological evaluation could 
be done in 293 of the 299 patients and six month follow up 
could not be done in 8, while 9 patients relapsed. The ﬁ  nal 
intent-to-treat cure rate was 94% for miltefosine (282 out of 
299). In the amphotericin B group, all 96 patients achieved 
ﬁ  nal cure and none of them relapsed. Since 3 patients had 
been withdrawn, the ﬁ  nal cure rate with this drug was 97% 
(96 out of 99). If we consider only those patients who were 
available for evaluation at 6 months, then the cure rate was 
282/291 (97%) for miltefosine and 96/96 (100%) for ampho-
tericin B (Sundar et al 2002).
Conclusions. These clinical trials established the safety and 
efﬁ  cacy of oral miltefosine in the treatment of VL in patients 
aged above 12 years. Treatment is associated with gastro-
intestinal adverse events (which are mild in most instances) 
and occasional severe complications like severe vomiting 
or diarrhea, nephro- or hepatotoxicity, which requires treat-
ment discontinuation. In females of child bearing potential, 
contraception for the duration of treatment and further two 
months must be ensured because of the teratogenic potential 
of the drug.
Pediatric trials
Clinical trials with miltefosine involved patients above the 
age of 12 years. However, children under 12 constitute a 
large proportion of patients with VL not only in India, but 
also in other endemic regions. For the drug to be used in 
practice, its safety and efﬁ  cacy was to be established in 
younger children. Two trials involving 119 children aged 
2–11 years were conducted.
Phase I/II pediatric trial
It enrolled 21 and 18 patients at two sites treated with 1.5 
and 2.5 mg/kg (10 mg capsules), respectively for 28 days. 
The entry criteria were similar to earlier studies, except that 
here they allowed for children with better hematological 
proﬁ  le (hemoglobin  6 gm/dl; leucocyte count  2000/µl; 
platelet count  50,000/µl) since this was the ﬁ  rst study 
in children. All patients achieved initial cure at the end of 
treatment, however, two patients in each group relapsed with 
clinical and parasitological features of VL. One patient in 
2.5 mg group was lost to follow up. The ﬁ  nal cure rates were 
by intention-to-treat analysis 90% and 83% in the 1.5 mg and 
2.5 mg groups, respectively, and by per protocol analysis 
19/21 (90%) and 15/17 (88%), respectively. There was no 
dose effect. While efﬁ  cacy was similar in the two groups, 
the dose of 2.5 mg/kg was chosen for practical reasons (same 
dose as for adults) (Sundar 2003).
Phase II pediatric trial
Four centers enrolled 20 children (mean age 7.8 years) each 
(n = 80) who received 28 days of miltefosine at a dose of 
2.5 mg/kg (including 19 (24%) patients who failed to respond 
to a previous course of antimony). One patient died of inter-
current pneumonia during ﬁ  rst week of treatment. In the 
remaining patients, treatment resulted in rapid improvement 
in clinical and laboratory parameters. They became afebrile 
by 6th day, spleen size regressed from a mean of 6.8 cm 
to 4.0 cm at 2 weeks of treatment and 1.5 cm at the end of 
treatment, and ﬁ  nally 0.3 cm at 6 month evaluation. All 79 
children who completed treatment achieved initial cure; one 
patient was lost to follow up while three patients relapsed. 
The ﬁ  nal cure rate was 94% (75/80; [95% CI-87–97]) on 
intention-to-treat basis and 96% (75/78; [95% CI-90–98]) 
on per-protocol analysis.
Similarly to other previous studies in adults and children, 
vomiting and diarrhea were the predominant adverse events, 
occurring in 21(26%) and 20(25%) of patients, respectively. 
Intensity was mild in most instances, with 1–2 episodes over 
the entire 28 days treatment duration. No nephrotoxicity was 
seen, though in a large proportion (55%) of children, asymp-
tomatic elevation of hepatic enzymes was seen, with values 
returning to normal by the second week while treatment was 
continued (Bhattacharya et al 2004).
Cutaneous leishmaniasis
Cutaneous leishmaniasis is caused by various species of 
Leishmania and occurs both in the Old and New World; 
clinical manifestations, natural history and response to 
treatment vary. While various topical, oral and injectable 
therapies have been tried over time, in general antimony 
(parenteral or pre-lesional), remains the most common 
treatment. In the ﬁ  rst dose-ﬁ  nding study of miltefosine for 
cutaneous leishmaniasis in Colombia (L. amazonensis and 
L. panamensis), the ﬁ  rst two groups of patients received 
50–100 mg for 21 days; of the 32 evaluable patients 21 
(66%) were cured. The next group was treated with 100 mg 
daily for one week followed by 150 mg daily up to day 20: 
the cures rates were 82% and 100% on intention-to-treat 
and per-protocol analysis, respectively. The fourth group 
received 150 mg daily for 28 days, with success rates of 
80% and 89% (intention-to-treat and per protocol). Only 
21% of patients complained of GI side effects. The most 
common and unusual ﬁ  nding was a dose-related complaint 
of a feeling of “motion sickness” lasting for 1–7 days in 
77 and 55% of the patients in the two higher dose groups 
(Soto et al 2001).Therapeutics and Clinical Risk Management 2007:3(5) 738
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The next study was a double-blind placebo controlled 
multicenter trial conducted in Colombia and Guatemala. 
Patients were randomized to receive either placebo or 
miltefosine 150 mg daily in patients weighing 45 kg, 
and 100 mg to those with 45 kg for 28 days. There was 
marked difference in the outcome between the two sites (and 
the species), and the ﬁ  nal cure rate were 82 (intent-to-treat) 
and 91% (per-protocol) in Colombia (L. v. panamensis) 
compared to 50% and 53%, in Guatemala (L. v. braziliensis) 
respectively. These cure rates were signiﬁ  cantly superior to 
the placebo groups (In Colombia 38% each both with ITT 
and PP analysis, whereas it was 20% and 21% in Guatemala, 
respectively), irrespective of the site. Though the drug was 
overall well-tolerated, nausea occurred in 36% of treatments, 
vomiting in 31%, motion sickness in 29%, headache 27%, 
and diarrhoea in 6%. Though 33% patients had an increase 
in serum creatinine, in all but one (1%) it was mild. Eleva-
tion of AST and ALT was seen in 8% and 10% patients, 
respectively. Thus, miltefosine may be used for cutaneous 
leishmaniasis due to L. v. panamensis in Colombia but not 
L. v. braziliensis in Guatemala (Soto et al 2004).
In a pilot study of 12 patients with diffuse cutaneous leish-
maniasis failing multiple previous treatment, were treated 
with miltefosine 2.5 mg/kg for and 100% improvement was 
seen in 7 patients, and 90%–95% in the remaining ﬁ  ve after 
two months of treatment(Soto and Soto 2006).
Treatment of HIV/VL co-infected patients
Treatment of VL in people with HIV is difﬁ  cult and relapse 
is the rule. 39 HIV-coinfected patients were treated under a 
compassionate use program of miltefosine. Most of them 
had already had several courses of various treatments; 41% 
achieved initial cure, and 23% improved on the second 
course of treatment, n/22 (41%) were cured initially and 
27% improved. Three (33%) of 9 and 1 (25%) of 4 patients 
had an initial cure after the third and fourth course, respec-
tively. In those with initial response, the median disease-free 
interval was in the range of 4–5 months. Tolerance to drug 
was good; 26% had vomiting, 10% each had diarrhea and 
nausea. One patient received miltefosine as maintenance 
therapy for two years, and tolerated it well (Sindermann 
et al 2004). Ritmeijer et al (2006) in a recent study, the ﬁ  rst 
done in Africa, randomized 580 patients, irrespective of the 
HIV status, to receive either oral miltefosine (100 mg per 
day for 28 days) or intramuscular SSG (20 mg/kg per day for 
30 days). Considering all patients irrespective of HIV status 
the initial and ﬁ  nal cure rate were similar (88% and 94% 
respectively for miltefosine and 88% and 89% for SSG) and 
mortality was lower with miltefosine (6% vs 12% on SSG), 
Among HIV-coinfected patients, miltefosine was judged safer 
but less effective than SSG.
Perspectives for use in practice
Miltefosine is the ﬁ  rst oral drug licensed for the treatment of 
leishmaniasis. As such, it is a major advance in that it makes 
home treatment possible, with the advantage of large-scale 
use. However, oral bioavailability exposes also the drug to 
misuse and untoward effects (toxicity, premature discontinu-
ation of therapy, failure, and development of resistance). The 
key questions are therefore how this drug performs in real-life 
and what the best conditions to deploy it are.
Though formally the results of a large phase IV study 
in India are not available, preliminary results (unpublished 
observations) indicate that the cure rate with a partly 
supervised regimen (adherence assessed based on weekly 
pill count) may be somewhat lower than in Phase II and III 
trials (were treatment was fully supervised). Sub-optimal 
compliance may be the cause. Miltefosine is still available 
freely in the private sector in India at a price which cannot be 
afforded by the typical cash starved patient in this area. Quick 
recovery (within 10 days most patients feel better) coupled 
with the high cost of the drug will likely motivate these 
patients to prematurely discontinue treatment (Sundar and 
Murray 2005). Miltefosine is now becoming publicly avail-
able at pilot scale at no cost to patients, but compliance post-
improvement will remain an important problem. A further 
problem if compliance is sub-optimal is the likelihood of the 
development of parasite resistance. Parasite resistance can be 
induced experimentally, and the long clinical half life (∼170 
hrs) makes miltefosine vulnerable to the development of 
resistance in endemic regions in which, like India, transmis-
sion is anthroponotic. The effects of the recent introduction 
of miltefosine for the treatment of canine leishmaniasis by 
Virbac in Southern Europe on the development of resistance 
in areas on zoonotic transmission are unknown.
For these reasons, the drug should be delivered to the 
patients under directly observed therapy either free or at a 
heavily subsidized cost to make it affordable.
A second important aspect is serious toxicity occurring 
in about 3% patients, which can generate sizeable numbers 
of casualties if hundreds of thousand of patients are to be 
treated. Every physician needs to be made aware of these 
toxicities, in order to be able to recognize them and stop 
treatment at once as these events manifest. In about 2% of 
these patients, severe vomiting and diarrhea or both can 
occur leading to rapid dehydration and its consequences. Therapeutics and Clinical Risk Management 2007:3(5) 739
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Renal and liver toxicity may develop before they become 
clinically manifest, and can be detected only by laboratory 
investigations.
A third precaution involves the teratogenic potential of 
this drug; females of child bearing potential constitute a 
signiﬁ  cant proportion of the patients and must avoid getting 
pregnant during treatment and for a further two months in 
view of the drug’s long half life. In the developing world 
this is a challenging task; a contraceptive effective for three 
months (eg, depot progesterone), should be mandatory for 
these patients, and in case of non-acceptance an alternative 
therapy should be considered for VL.
The ﬁ  rst country to grant marketing authorization to 
miltefosine for VL was India in 2002, followed by Germany 
and Colombia; approval will be sought in Nepal and 
Bangladesh. It is not registered elsewhere, and for the time 
being is not on the WHO list of essential drugs.
The three countries in the Indian sub-continent, India, 
Nepal and Bangladesh have joined hands in an elimination 
program for VL, and hope to eliminate the disease by 2015; 
in this endeavor miltefosine is going to be an important tool. 
However, a 28 day twice daily regimen and frequent gastroin-
testinal adverse events makes it imperative that the dispensing 
physicians are educated as to how counseling every patient 
before the drug is dispensed. Teratogenic effect of the drug and 
largely illiterate female population puts this drug in a vulner-
able position. It is therefore important to devise strategies to 
monitor the effects of miltefosine (both in terms of real-life 
efﬁ  cacy and toxicity) during large-scale deployment.
Miltefosine, being an oral drug with long half-life 
has great potential to be one component of combination 
chemotherapy. Unfortunately not many antileishmanial 
drugs are available for use in combination as conventional 
amphotericin B deoxycholate can not be used as the country 
does not have the capacity to treat many patients. Current 
options for combination treatment are miltefosine, liposomal 
amphotericin B (AmBisome®) and paromomycin (recently 
granted marketing authorization in India). A large dose of 
AmBisome® can be given as a bolus in single dose (ca. 90% 
effective on its own) (Sundar et al 2001, 2003), followed by 
eg, two weeks of miltefosine (ca. 89% effective on its own) 
(Sundar et al 2000). The biggest limitation of this approach 
is the cost of drugs, even at the prices recently announced for 
AmBisome® (now $20 per vial) and miltefosine (conditional 
to the size of the order: WHO recently obtained an average 
of $64/treatment for ∼20,000 treatments).
This is the time to launch studies to test the combination 
to make the treatment of VL more effective, attractive and 
available to all sections of the society. This will also improve 
compliance and prolong the useful therapeutic life-span of 
the drugs.
Disclaimer
PO is a staff member of the WHO; the authors alone are 
responsible for the views expressed in this publication and 
they do not necessarily represent the decisions, policy, and 
views of the WHO.
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